China is pissed off over the new trade deal between Taiwan and the United States. Officials in Beijing say Donald Trump’s team is draining Taiwan’s economy whileChina is pissed off over the new trade deal between Taiwan and the United States. Officials in Beijing say Donald Trump’s team is draining Taiwan’s economy while

China condemns U.S. trade deal draining Taiwan’s economy

China is pissed off over the new trade deal between Taiwan and the United States. Officials in Beijing say Donald Trump’s team is draining Taiwan’s economy while pretending it’s some big win for both sides. They’re not buying it.

The deal, signed last week, cuts U.S. tariffs on Taiwanese exports down to 15%. In return, Taiwan is throwing in half a trillion dollars. That’s $250 billion in direct investment into U.S. tech and chip factories, and another $250 billion in credit support for its own companies expanding in America.

Peng Qingen from China’s Taiwan Affairs Office didn’t hold back. On Wednesday, he said the deal would “only drain Taiwan’s economic interests,” and slammed Taiwan’s ruling Democratic Progressive Party, or DPP, for letting the U.S. “hollow out” the island’s most important industries.

That was his exact quote. Peng also said the DPP was selling out local jobs just to help the U.S. boost its tech sector.

Taiwan funds chip expansion as U.S. slashes tariffs

The deal gives Taiwan a few perks. It gets higher quotas to ship chips to the U.S. without tariffs. It also gets full waivers on generic drugs, airplane parts, and raw materials that the U.S. doesn’t produce itself.

In return, the DPP promised $250 billion in new projects inside the U.S., from chip fabrication to artificial intelligence labs. Another $250 billion in credit is being handed out by Taiwan’s government to help companies expand production abroad.

Howard Lutnick, Trump’s Commerce Secretary, told CNBC on Thursday the U.S. wants 40% of Taiwan’s chip supply chain to be built out in America. He didn’t say how fast or which parts, but that was the target. It’s a massive goal.

TSMC, the world’s largest contract chipmaker, is already building in Arizona. They’ve pledged $165 billion to build fabs and an R&D center. That’s just the start. Reports say they might add another four to six plants, which would take the total above ten.

Taiwan’s vice premier, Cheng Li-chiun, responded to Lutnick’s comment by saying the U.S. chip plan isn’t just about Taiwan. “Other countries and American firms are part of this too,” she said. She made it clear Taiwan isn’t giving away its top tech. The most advanced nodes will stay in Taiwan.

China warns of economic sabotage and blasts DPP

Beijing says this whole thing is a trap. They accuse the U.S. of trying to use Taiwan as a tool to hold back China.

Peng said labor costs for TSMC’s U.S. factories are more than double what they are at home. He said pushing Taiwanese companies to build expensive plants in America just to create “so-called high-paying jobs for Americans” is a strategy that will destroy Taiwan’s own tech foundation.

Last week, Beijing said it “firmly opposed” any agreement between Taiwan and countries that have diplomatic ties with China. They also told Washington to stick to the one-China principle.

Xi Jinping still says unification with Taiwan is “a historical inevitability.” Taiwan isn’t having it. The government there has always rejected China’s claim.

Right now, Taiwan still dominates global chip manufacturing. TSMC alone makes most of the world’s advanced chips.

Almost one-third of the world’s new computing power is estimated to come from Taiwan. That’s why Trump’s team is going all-in. They want to lock Taiwan deeper into the U.S. economy while China steps up political and military pressure on the island.

Get seen where it counts. Advertise in Cryptopolitan Research and reach crypto’s sharpest investors and builders.

Market Opportunity
Union Logo
Union Price(U)
$0.002444
$0.002444$0.002444
-0.97%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26